Laminin-332（LM-332）是基底膜的重要组分。最近，在多种自身免疫疾病中报道了Laminin-332的自身抗体。其中许多自身免疫疾病具有高发癌症的发病率。通过使用Laminin-332Pemphigoid（LM-332Pg）作为原型，强调了Laminin-332自身抗体的重要性及其与癌症的关系。目标是确定存在自身抗体Laminin-332的多种自身免疫疾病，并确定其中的癌症发病率。同时，通过以Laminin-332Pemphigoid（LM-332Pg）患者为原型，比较有癌症和没有癌症的LM-332Pg患者的临床特征。通过检测癌症的出现时间，可以确定Laminin-332自身抗体对预后的影响。 我们进行了文献搜索，以确定存在Laminin-332自身抗体的自身免疫和炎症性疾病。随后，确定了这些自身免疫疾病中的癌症发病率。进行了关于LM-332Pg患者的文献检索，以确定癌症发病率和临床结果，以探讨是否存在相关性。 最近的研究发现，在系统性红斑狼疮（SLE）、银屑病、细支气管炎（BO）、移植宿主病（GVH）、大疱性类天疱疮（BP）、扁平苔藓（LP）、获得性表皮溶解性水泡症（EBA）和膜性肾小球肾炎（MGN）中检测到了Laminin-332的自身抗体。这些自身免疫疾病中，包括原发性Sjögren综合征（pSS）、系统性硬化症（SS）、皮肌炎（DM）、多发性硬化症（MS）、免疫性血小板减少性紫癜（ITP）和类风湿关节炎（RA）在内的疾病中都报道了较高的癌症发病率。数据分析表明，LM-332Pg患者患上卵巢癌、子宫癌、肺癌、胃癌和白血病的风险较高。与全球癌症发病率相比，乳腺癌的发病率较低。在发现/诊断LM-332Pg之后被诊断为癌症的患者，较之于发现癌症先于LM-332Pg的患者，其死亡率较高，缓解率较低。研究发现，Laminin-332自身抗体的水平与是否存在癌症相关。 初步分析表明，Laminin-332自身抗体存在于多种自身免疫疾病中，这些疾病也具有较高的癌症发病率。详细分析现有数据强调了在癌症诊断之后发展为LM-332Pg的患者相比于在LM-332Pg以前就患有癌症的患者，其预后更为有利。初步数据表明，Laminin-332自身抗体可能成为某些患者的重要生物标志物，用于与可能的癌症发病率相关性的关联。 版权所有 © 2023 Elsevier B.V. All rights reserved.

Laminin-332 is an important component of the basement membrane. Recently, autoantibodies to Laminin-332 have been described in several autoimmune diseases. Many of these autoimmune diseases have a high incidence of malignancy. The importance of Laminin-332 autoantibodies and its relationship to malignancy is highlighted by using Laminin-332 Pemphigoid (LM-332Pg) as a prototype.To identify several autoimmune diseases that have autoantibodies to Laminin-332 present, and to determine the prevalence of malignancy in them. Using Laminin-332 Pemphigoid (LM-332Pg) as a prototype, to compare clinical profiles of LM-332Pg patients with and without cancer. By identifying the temporal detection of cancer, can the influence of autoantibodies to Laminin-332 on prognosis be determined.A literature search was conducted to identify autoimmune and inflammatory diseases in which autoantibodies to Laminin-332 were present. Subsequently, the rate of malignancy in these autoimmune diseases was determined. A search for publications on LM-332Pg patients to determine cancer rates and clinical outcomes to examine if a relationship can be proposed, was performed.Autoantibodies to Laminin-332 were detected in recent studies of systemic lupus erythematosus (SLE), psoriasis, bronchiolitis obliterans (BO), graft-vs-host disease (GVH), bullous pemphigoid (BP), lichen planus (LP), epidermolysis bullosa acquisita (EBA), and membranous glomerulonephropathy (MGN). A high incidence of cancer rate was reported in these autoimmune diseases including primary Sjögren's syndrome (pSS), systemic sclerosis (SS), dermatomyositis (DM), multiple sclerosis (MS), immune thrombocytopenia purpura (ITP), and rheumatoid arthritis (RA). Data analysis demonstrated that LM-332Pg patients had a higher risk of developing ovarian, uterine, lung, gastric cancers and leukemia. The incidence for breast cancer was lower, when compared with global cancer rates. Patients diagnosed with cancer after the presence of LM-332Pg had higher rates of mortality and lower rates of remission, compared to those diagnosed with cancer prior to the discovery/diagnosis of LM-332Pg. When studied, levels of Laminin-332 autoantibodies correlated with the presence or absence of malignancy.Preliminary analysis suggests that autoantibodies to Laminin-332 are present in multiple autoimmune diseases, which also have a high incidence of malignancy. Detailed analysis of available data highlights that patients who developed LM-332Pg after cancer was diagnosed, had a more favorable prognosis, compared to patients who developed cancer when LM-332Pg was previously present. Preliminary data would suggest that autoantibodies to Laminin-332 could serve as an important biomarker in certain patients, for correlation with possible incidence of malignancy.Copyright © 2023. Published by Elsevier B.V.